Intrafraction organ movement in adaptive MR-guided radiotherapy of abdominal lesions – dosimetric impact and how to detect its extent in advance

Table 1 Treatment characteristics

Patient No.	Treatment localization	OAR	No. of fractions	Prescribed dose (Gy)	OAR constraint D_0.5cc (Gy)
1	Liver	Small bowel	10	50	43.5
2	Liver	Stomach	5	50	35
		Duodenum			35
		Esophagus			34
3	Liver	Small bowel	10	50	43.5
4	Liver	Small bowel	10	50	43.5
5	Liver	Duodenum	10	50	43.5
6	Adrenal gland	Small bowel	5	50	35
7	Liver	Small bowel	5	50	35
8	Liver	Duodenum	5	50	35
9	Liver	Stomach	5	50	35
10	Liver	Small bowel	10	50	43.5
		Duodenum			43.5
11	Lymph node	Stomach	6	30	37
12	Adrenal gland	Stomach	5	50	35
13	Adrenal gland	Stomach	8	40	40
		Small bowel			40
14	Abdominal lymph node	Small bowel	7	35	37
15	Liver	Small bowel	10	50	43.5
16	Liver	Duodenum	10	50	43.5
17	Adrenal gland	Small bowel	10	50	43.5
		Stomach			42.5
18	Adrenal gland	Duodenum	5	50	35
19	Pancreas	Small bowel	5	50	35
20	Liver	Small bowel	10	50	43

Overview over treatment localization, OAR used for evaluation, number of treatment fractions, prescribed dose and tolerance dose of the OAR for the respective prescription. For all patients, dose distribution inside the PTV is inhomogeneous with an allowed maximum dose of 125% of the prescribed dose

ISSN: 1748-717X